Recent advances in nanoparticle technology demonstrate significant therapeutic potential across multiple medical domains. Novel developments include intranasal nanoparticle adjuvants targeting the STING pathway, which generate robust mucosal and systemic immunity against coronaviruses while converting traditional flu vaccines into effective nasal formulations. Optimized lipid nanoparticle-based prime editing systems enable efficient gene editing and disease correction in human cells with improved delivery outcomes. Additionally, nanoparticles show promise in cancer treatment through enhanced accumulation near micrometastases, improved early-stage metastasis detection, and immunotherapeutic applications that trigger viral defense responses and activate B cell immunity. Further breakthroughs include nanovaccines enhancing dendritic cell communication for improved T cell activation and dual-acting lipid nanoparticles combining effector T cell stimulation with exhaustion inhibition, offering transformative approaches to previously difficult-to-treat malignancies.

This open-access protocol presents a comprehensive methodology for analyzing three-dimensional single-cell imaging of tumor-natural killer cell interactions within multi-cell-type tumor organoid models. Published in BMC Methods in June 2026, the research enables detailed visualization and characterization of dynamic cellular interactions at the individual cell level. The protocol advances understanding of immune cell behavior within complex tumor microenvironments by utilizing sophisticated imaging techniques combined with organoid technology. This approach facilitates investigation of natural killer cell cytotoxic mechanisms and tumor cell responses in physiologically relevant conditions, offering valuable insights for immunotherapy development and personalized cancer research applications.

The technology could help researchers identify promising cancer therapies more rapidly and provide a way to test treatments on a patient's own tumor cells, ...

One of the most promising approaches is in vivo CAR-T cell engineering using lipid nanoparticles (LNPs) loaded with mRNA to reprogram endogenous T cells ...

Organoid-based co-cultures are also being developed and screened for advanced immunotherapies. These include testing chimeric antigen receptor (CAR) T cells, ...

Wound healing represents a complex physiological process crucial for treating chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Recent research has identified galangin and related flavonoids as promising therapeutic agents due to their multifaceted bioactivities. These natural compounds effectively modulate inflammation, reduce oxidative stress, stimulate fibroblast proliferation, facilitate extracellular matrix remodeling, and inhibit microbial growth. Advanced wound care therapies now incorporate multiple mechanisms including growth factors, antimicrobial agents, anti-inflammatory drugs, and extracellular matrix modulators. The integration of galangin into therapeutic protocols represents a significant advancement in wound healing management, offering potential improvements in healing outcomes for patients with compromised wound repair mechanisms.

Penn State researchers have developed and tested CaroFlex, an innovative soft 3D-printed implant designed to reduce blood pressure through a novel therapeutic approach. The device attaches directly to the carotid artery without requiring surgical stitches, functioning by stimulating the baroreflex—a natural physiological mechanism that regulates blood pressure. Preliminary trials conducted on rodent models demonstrated promising results, with participants experiencing average blood pressure reductions exceeding 15 percent across multiple operational modes. This advancement represents a significant breakthrough in minimally invasive cardiovascular intervention technology, offering potential therapeutic benefits for hypertension management with reduced surgical complexity.

Natural killer cells have emerged as a promising immunotherapeutic platform for cancer treatment, offering advantages over traditional therapies by recognizing and eliminating tumor cells without prior sensitization. This review examines recent advances in NK cell engineering, including chimeric antigen receptor technology, cytokine armoring, and CRISPR-based genetic modifications that enhance specificity and antitumor efficacy. Multiple NK cell sources—peripheral blood, cord blood, cell lines, and induced pluripotent stem cell-derived platforms—provide diverse therapeutic options. Emerging approaches utilizing synthetic biology, nanotechnology, and metabolic reprogramming strengthen resistance to immunosuppressive tumor microenvironments. Preliminary clinical trials demonstrate promising efficacy and favorable safety profiles compared to CAR-T therapies, particularly in hematological malignancies. However, challenges regarding in vivo persistence and long-term durability require continued investigation to fully realize NK cell immunotherapy's potential.

This article explores advanced delivery strategies for generating CAR-T cells directly within the body, a significant advancement in cancer immunotherapy. Researchers are engineering viral vectors and nanocarriers with T cell-targeting ligands to achieve precise genetic delivery while minimizing off-target effects. Key approaches leverage highly expressed T cell markers such as CD3, CD8, and CD28. Notable developments include Umoja's anti-CD3 modified lentivirus, which successfully generated anti-CD19 CAR cells in xenograft models, and CD3-targeted lipid nanoparticles that delivered CAR constructs to circulating T cells with sustained anti-tumor effects lasting 41 days. These in vivo engineering platforms demonstrate comparable efficacy to traditional ex vivo therapies while offering potential advantages in accessibility and manufacturing efficiency for cancer treatment.

Functional profiling is a precision oncology platform that assesses tumor response to drugs ex vivo, capturing dynamic phenotypic responses to therapeutic ...

Studies of alcohol’s effects on health have offered contradictory findings, with some suggesting a glass of red wine a day is beneficial and others saying even a drop of booze is too much. A new review attempting to clarify the risks finds more than 60 diseases, based on the World Health Organization’s International Classification of Diseases, are 100 percent attributable to consuming alcohol. But the review also finds that some of the damage can be slowed or reversed by cutting down or quitting drinking.

Cervical non-invasive vagus nerve stimulation (nVNS) has emerged as a practical neuromodulation approach with FDA clearance for primary headache disorders, yet questions persist regarding its efficacy. This comprehensive review synthesizes anatomical, biophysical, physiological, and clinical evidence demonstrating that nVNS reliably activates vagal pathways without surgical intervention. The analysis encompasses cervical vagus anatomy, biophysical mechanisms supporting target engagement, and computational modeling confirming recruitment of myelinated vagal fibers. Converging evidence from functional imaging, electrophysiology, immune studies, and autonomic biomarkers reveals consistent modulation of canonical vagal projection sites and parasympathetic activation. Sham-controlled randomized trials in cluster headache and migraine demonstrate nVNS superiority over placebo in both acute and preventive outcomes with favorable safety profiles, establishing a robust mechanistic and clinical foundation for this therapeutic approach.

Digital twins represent a paradigm shift in clinical trial methodology by enabling AI-generated virtual patient models trained on historical data to predict patient responses under control conditions. This innovation challenges the longstanding requirement for live placebo arms, reducing trial sizes, compressing timelines, and lowering costs while minimizing patient exposure to ineffective treatments. With regulatory validation from both the EMA and FDA, alongside real-world implementation by pharmaceutical leaders like Sanofi, digital twin technology has transitioned from theoretical to practical application. These individual-level computational models generate statistically valid comparative evidence without full randomization to placebo, fundamentally transforming drug development efficiency and ethical patient outcomes.

The integration of multiomics technologies with artificial intelligence represents a transformative paradigm in precision medicine and drug discovery. By combining genomic, transcriptomic, proteomic, and metabolomic analyses with advanced deep learning algorithms, researchers can decipher complex biological datasets and identify disease patterns with unprecedented precision. This synergistic approach accelerates target identification, optimizes lead compounds, and enhances clinical trial design across diverse therapeutic areas including oncology and neurodegenerative diseases. While challenges regarding data harmonization, reproducibility, and algorithmic bias remain, multiomics-AI integration enables hypothesis generation and data-driven discovery that fundamentally advances translational medicine. This convergence provides distinct competitive advantages in virtual screening, pharmacokinetic modeling, and safety assessment, heralding a new era in evidence-based therapeutic development.

This article from the Journal of Chest Surgery examines the application of organoids in cancer research. Organoids, three-dimensional tissue structures that recapitulate organ architecture and function, represent a significant advancement in cancer modeling and therapeutic development. The publication explores how organoid technology provides improved platforms for studying tumor biology, drug response, and personalized medicine approaches. By bridging the gap between traditional two-dimensional cell cultures and in vivo animal models, organoids enable researchers to investigate cancer mechanisms more accurately while reducing reliance on animal testing. The article discusses the role of organoids in advancing precision oncology and their potential to enhance treatment outcomes in thoracic malignancies, contributing to the evolving landscape of cancer research methodologies.

Accurately predicting the outcome of drug candidates remains a central challenge in preclinical research. Traditionally, this has relied on the use of 2D cell cultures or animal models. In recent decades, significant efforts have been made to develop 3D in vitro models that better recapitulate in vivo physiology, while also minimizing the use of animal testing. In this report, we discuss spheroids, organoids, organ-on-chips, and scaffolds as well as assess their relevance as models for heart, gut, brain, liver, and tumor tissue. It appears that spheroids are uniquely appropriate for modeling tumors, where features like hypoxia - typically a limitation of 3D models - mirror the natural tumor microenvironment. The human heart, gut, brain and liver are complex organs that are still difficult to model with conventional methods; in these tissues, 3D models such as organoids and organ-on-chips appear to be the most physiologically accurate alternative. Across all these models, scaffolds and hydrogels play a central role in mimicking the native extracellular matrix and promoting physiologically relevant cell behaviour. 

Examine how digital twins in clinical trials function as virtual control arms. This report reviews FDA guidance, AI models, and implementation requirements.

Portions plus petites, protéines en extra… Les médicaments pour la perte de poids étant de plus en plus répandus, les restaurants américains modifient leur offre pour répondre aux besoins de leurs clients.

Le fast-track national a pour objectif de réduire significativement les délais d’évaluation des demandes d’autorisation, tout en garantissant la qualité et la rigueur éthique et scientifique de l’évaluation. Ce dispositif pilote s’adresse aux essais mononationaux de phase I ou de phase I/II intégrées, répondant à au moins l’un des critères suivants : Maladies graves, rares ou invalidantes pour lesquelles aucun traitement approprié n’existe ; Premier essai dans une classe thérapeutique (avec un mécanisme d’action entièrement nouveau) ; Inclusion d’adolescents (12 à 18 ans) dans des essais chez l’adulte.

Organoids and Organ-on-a-Chip technology have been considered a paradigm shift in cell culture for over a decade. However, fundamental usability and logistics aspects have hampered widespread adoption, as both require deep biological expertise and cumbersome logistics of cell materials. MIMETAS has invested in productization of organoids in its perfused high throughput OrganoPlate platform. Its OrganoReady® product line comprises of 64 adult stem cell derived colon organoids grown as perfused tubules that are delivered ready-to-use to the bench of the scientist. Turnkey assays allow monitoring of barrier function under toxic and inflammatory challenges. New products for the kidney are available in early access, and next generation models comprising fully vascularized, stroma and immune competent liver, lung and tumor tissues are available in a services setting.